Predictive role of hs-C-reactive protein in patients with antiphospholipid syndrome

Immunobiology

Volumn 210, Issue 10, 2005, Pages 755-760

  Miesbach, Wolfgang ^a   Gökpinar, Buket ^a   Gilzinger, Andreas ^a   Claus, Detlef ^b   Scharrer, Inge ^a  

^a GOETHE UNIVERSITY   (Germany)

^b KLINIKUM DARMSTADT   (Germany)

Author keywords

Anti cardiolipin antibodies; Antiphospholipid syndrome; CRP; Neurological manifestation; Non thrombotic manifestation; Risk factors; Stroke

Indexed keywords

ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; CLOPIDOGREL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; WARFARIN;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD ANALYSIS; BRAIN INFARCTION; BRAIN RADIOGRAPHY; CARDIOVASCULAR RISK; CLINICAL EXAMINATION; CLINICAL FEATURE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

EID: 28044455696     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2005.10.006     Document Type: Article

References (29)

1. L.M. Biasucci G. Liuzzo R.L. Grillo G. Caligiuri A.G. Rebuzzi A. Buffon F. Summaria F. Ginnetti G. Fadda A. Maseri Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability Circulation 99 1999 855-860
2. J.T. Brandt D.A. Triplett B. Alving I. Scharrer Criteria for the diagnosis of lupus anticoagulants: An update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH Thromb. Haemostasis 74 1995 1185-1190
3. A.L. Campbell S.S. Pierangeli S. Wellhausen E.N. Harris Comparison of the effect of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation Thromb. Haemostasis 73 1995 529-534
4. J. Cermak N.S. Key R.R. Bach J. Balla H.S. Jacob G.M. Vercelotti C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor Blood 82 1993 513-520
5. J. Chapman M. Cohen-Armin Y. Shoenfeld A.D. Korczyn Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes Lupus 8 1999 127-133
6. J. Danesh P. Whincup M. Walker L. Lennon A. Thomson P. Appleby J.R. Gallimore M.B. Pepys Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses BMJ 321 2000 199-204
7. J. Danesh J.G. Wheeler G.M. Hirschfield S. Eda G. Eiriksdottir A. Rumley G.D. Lowe M.B. Pepys V. Gudnason C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease N. Engl. J. Med. 350 2004 1387-1397
8. C.A. Dinarello Biological basis for interleukin-1 in disease Blood 87 1996 2095-2147
9. P.M. Dobado-Berrios C. Lopez-Pedreda F. Velazco M.J. Cuadrado The role of tissue factor in the antiphospholipid syndrome Arthritis. Rheum. 44 2001 2467-2476
10. D. Erkan Y. Yazici M.G. Peterson L. Sammaritano M.D. Lockshin A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome Rheumatology 41 2002 924-929
11. M. Galli D. Luciani G. Bertolini T. Barbui Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature Blood 101 2003 1827-1832
12. E.N. Harris S.S. Pierangeli Revisiting the anticardiolipin test and its standardization Lupus 11 2002 269-275
13. S.R. Levine R.L. Brey K.L. Sawaya L. Salowich-Palm J. Kokkinos B. Kostrzema M. Perry S. Havstad J. Carey Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome Ann. Neurol. 38 1995 119-124
14. S.R. Levine L. Salowich-Palm K.L. Sawaya M. Perry H.J. Spencer H.J. Winkler Z. Alam J.L. Carey IgG anticardiolipin antibody titer>40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study Stroke 28 1997 1660-1665
15. B. Lindahl H. Toss A. Siegbahn P. Venge L. Wallentin Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease N. Engl. J. Med. 343 2000 1139-1147
16. I.J. Mackie S. Donohoe S.J. Machin Lupus anticoagulant measurement. In: M.A. Khamashta (Ed.), Hughes Syndrome. Antiphospholipid Syndrome 2000 Springer London pp. 214-225
17. P.L. Meroni E. Raschi M. Camera C. Testoni F. Nicoletti A. Tincani Endothelial activation by aPL. A potential pathogenetic mechanism for the clinical manifestations of the syndrome J. Autoimmun. 15 2000 237-240
18. Miesbach, W., Gilzinger, A., Gökpinar, B., Claus, D., Scharrer, I., 2005. Prevalence of antiphospholipid antibodies in patients with neurological symptoms. Clin. Neurol. Neurosurg, in press. doi:10.1016/ j.clineuro.2005.03.005
19. S. Mohan G.A. Stouffer C. Patterson The utility of C-reactive protein in the detection of atherothrombotic vascular disease: Ready for prime time J. Thromb. Haemostasis 2 2004 1238-1239
20. P.M. Ridker High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease Circulation 103 2001 1813-1818
21. P.M. Ridker Clinical application of C-reactive protein for cardiovascular disease detection and prevention Circulation 107 2003 363-369
22. R.S. Rosenson W. Koenig High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease Curr. Opin. Cardiol. 17 2002 325-331
23. R.S. Rosenson W. Koenig Utility of inflammatory markers in the management of coronary artery disease Am. J. Cardiol. 92 2003 10i-18i
24. D. Tanne L. D'Olhaberriague A.M. Trivedi L. Salowich-Palm L.R. Schultz S.R. Levine Anticardiolipin antibodies and mortality in patients with ischemic stroke: A prospective follow-up study Neuroepidemiology 21 2002 93-99
25. P. Thiagarajan V. Pengo S.S. Shapiro The use of the dilute Russel viper venome time for the diagnosis of lupus anticoagulants Blood 68 1986 869-874
26. D.A. Triplett K.F. Stocker G.A. Unger The Textarin/Ecarin ratio: A confirmatory test for lupus anticoagulants Thromb. Haemostasis 70 1993 925-931
27. W.A. Wilson A.E. Gharavi T. Koike M.D. Lockshin D.W. Branch J.C. Piette R. Brey R. Derksen E.N. Harris G.R. Hughes D.A. Triplett M.A. Khamashta International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop Arthritis Rheum. 42 1999 1309-1311
28. R.Y. Zee H.H. Hegener A. Fernandez-Cruz K. Lindpaintner C-reactive gene polymorphisms and the incidence of post-angioplasty restenosis Atherosclerosis 176 2004 393-396
29. L. Ziporen Y. Shoenfeld Y. Levy A.D. Korczyn Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies J. Clin. Invest. 100 1997 613-619